Small, suspended, post COVID randomized trial, guselkumab failed to show efficacy at reducing proteinuria in 33 SLE pts. Wk24 results, 56% placebo vs. 35% GUS for primary end point., No differences in secondary outcomes or adverse events https://t.co/27imkXkbUn https://t.co/yGdDQlu5v3